Intraocular Pressure Lowering Effects of the Renin Inhibitor ABBOTT-64662 Diacetate in Animals

Abstract
Corneal application of enalkiren (ABBOTT-64662), [N-(3-amino-3-methyl-1-oxobutyl)-4-methoxy-L-phenylalanyl]-N-[(1S, 2R, 3S)-1-(cyclohexylmethyl)-2,3-di-hydroxy-5-methylhexyl]-L-histidinamide], a renin inhibitor compound, lowered intraocular pressure (IOP) in unanesthetized rabbits and anesthetized monkeys. IOP was significantly decreased for at least 60 minutes after administration of a 0.3% solution of enalkiren in monkeys and for at least 90 minutes after the administration of 0.1% and 0.3% solutions in rabbits. Enalkiren did not affect systemic blood pressure of heart rate in anesthetized monkeys after topical application to the cornea. The IOP lowering activity of enalkiren suggests a potential functional role for the renin angiotensin system in the modulation of IOP.